Novo Nordisk sets five-plus blockbuster targets by 2030; NVO slips
Novo Nordisk said it targets over five new blockbusters by 2030, but provided limited near-term catalysts, with investors citing competition concerns from Eli Lilly. U.S.-listed NVO shares were down 5% at the time of writing.
Novo Nordisk (NVO) was in focus on Monday after the drugmaker set out its long-term growth targets, but it did not give investors enough concrete near-term catalysts to ease concerns about competition from Eli Lilly (LLY). -listed NVO shares were down 5% at the time of writing.